Loading
A phase 3 trial of Oxaliplatin and Bevacizumab in colorectal cancer, run by Akeso, now recruiting.
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06951503 by Akeso, with 560 participants planned, started 2025-05-27 and due to reach its primary completion in 2027-01-13. Interventions recorded: AK112, Oxaliplatin, Irinotecan, Leucovorin and 5-FU and Bevacizumab.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Oxaliplatin, Monoclonal antibodies, Colorectal cancer and the tag pipeline.